Skip to main content

Table 3 Characteristics of IVF/ICSI-ET

From: Effects of localisation of uterine adenomyosis on outcome of in vitro fertilisation/intracytoplasmic sperm injection fresh and frozen-thawed embryo transfer cycles: a multicentre retrospective cohort study

  Advanced group (n = 40) Extrinsic group (n = 9) Intrinsic group (n = 3) P-value
Number of oocyte retrieval cycles 2 (1–9) 2 (1–4) 1 0.210
Type of controlled ovarian stimulation, n (%)     0.068
Short 49/111 (44.1) 4/21 (19) 0/3  
Long 26/111 (23.4) 11/21 (52.4) 1/3 (33.3)  
Ultra-long 16/111 (14.4) 2/21 (9.5) 1/3 (33.3)  
GnRH antagonist 15/111 (13.5) 3/21 (14.3) 1/3 (33.3)  
Others 5/111 (4.5) 1/21 (4.8) 0/3  
Total dose of gonadotropin used (IU) 2400 (225–6750) 2250 (600–2250) 1425 (1025–2625) 0.162
Number of oocytes retrieved 2 (0–15) 4 (1–11) 8 (8–14) 0.008
Fertilisation method, n (%)     0.616
ICSI 35/106 (33.0) 6/21 (28.6) 2/3 (66.7)  
IVF 67/106 (63.2) 14/21 (66.7) 1/3 (33.3)  
Mixed 4/106 (3.8) 1/21 (4.7) 0/3  
Number of ET cycles 2 (1–8) 3 (2–5) 3 (2–4) 0.129
Number of ET/cycles 1 (1–2) 1 (1–2) 1 (1–2) 0.802
ET type, n (%)     0.083
Fresh 49/100 (49) 11/27 (40.7) 1/9 (11.1)  
Frozen-thawed 51/100 (51) 16/27 (59.3) 8/9 (88.9)  
Embryo quality, (%)     0.034
Good 77/100 (77) 16/27 (59.3) 9/9 (100)  
Long-term pituitary down-regulation before ET, n (%) 20/100 (20) 1/27 (3.7) 0/9 0.048
  1. IVF in vitro fertilisation; ICSI intracytoplasmic sperm injection; ET embryo transfer; GnRH gonadotropin-releasing hormone